Results 361 to 370 of about 146,874 (392)
Some of the next articles are maybe not open access.
Trastuzumab-Induced Cardiomyopathy
Cardiology Clinics, 2019Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ...
Rachel Barish, Emily Gates, Ana Barac
openaire +3 more sources
Trastuzumab-Induced Hepatotoxicity
Annals of Pharmacotherapy, 2008Objective: To report a case of probable trastuzumab-induced hepatotoxicity. Case Summary: A 54-yoar-old African American woman presented with locally advanced right-sided breast cancer that was found to be strongly positive for human epidermal growth factor receptor 2 (HER2) by fluorescence in situ hybridization.
Sridhar Srinivasan +3 more
openaire +3 more sources
Ado-Trastuzumab Emtansine [PDF]
, 2015 Ado-trastuzumab emtansine (T-DM1 or KadcylaTM) is an antibody–drug conjugate (ADC) designed to deliver the antimitotic mertansine (DM1) drug to epithelial cancer cells overexpressing the oncoprotein HER2. T-DM1 has been approved in many countries for HER2-positive metastatic breast cancer (MBC) patients and has recently entered a phase 3 clinical trial
Yun Luo, Jerome J. Lacroix, Sunil Prabhu
openaire +1 more source
Trastuzumab: hopes and realities
The Lancet Oncology, 2002Despite improvements in care of patients with breast cancer, up to half develop refractory or resistant disease. There is therefore a need for new, modified anticancer therapies with greater effectiveness, tolerability to patients, and tumour specificity.
openaire +3 more sources
Journal of Clinical Oncology, 2019
PURPOSE Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity.
Hideaki Takahashi +15 more
semanticscholar +1 more source
PURPOSE Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity.
Hideaki Takahashi +15 more
semanticscholar +1 more source
Perspective of trastuzumab treatment
Breast Cancer, 2007Trastuzumab (Herceptin) has many benefits for metastatic breast cancer patients with HER2 overexpression/amplification. Trastuzumab alone or trastuzumab in combination with chemotherapy regimens are standard treatment worldwide as first line therapy for metastatic breast cancer patients with HER2 overexpression/amplification.
openaire +2 more sources
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
Cancer Chemotherapy and Pharmacology, 2004The majority of patients who initially respond to trastuzumab will progress within 1 year. Currently, patients who progress after trastuzumab-based therapy are often maintained on trastuzumab combined with a different chemotherapeutic agent, such as vinorelbine.
Rita Nahta, Francisco J. Esteva
openaire +3 more sources
Optimal duration of therapy with trastuzumab
Seminars in Oncology, 2001One of the primary objectives of early clinical drug development is to determine the optimal dose and schedule of administration of the drug under study. If this objective is accomplished, subsequent clinical trials can truly evaluate the antitumor efficacy, tolerability, and safety of the new drug, and the appropriate assessment of benefit/risk can be
openaire +3 more sources
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly